Ross Moat
Corporate Officer/Principal chez KINIKSA PHARMACEUTICALS, LTD.
Fortune : 321 125 $ au 31/03/2024
Profil
Ross Moat is currently the Chief Commercial Officer at Kiniksa Pharmaceuticals Ltd.
He previously worked as the General Manager at Synageva BioPharma Corp.
and as the VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. Mr. Moat completed his undergraduate degree at Middlesex University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/04/2024 | 16 276 ( 0,04% ) | 321 125 $ | 31/03/2024 |
Postes actifs de Ross Moat
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01/02/2021 |
Anciens postes connus de Ross Moat
| Sociétés | Poste | Fin |
|---|---|---|
| AVEXIS INC | Sales & Marketing | 01/06/2019 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Formation de Ross Moat
| Middlesex University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
